Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587636 · ClinicalTrials.gov registry record · Phase 2
Liposome Bupivacaine Interscalene Total Shoulder
A Phase 2 study of Acute Pain, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT03587636: Completed Phase 2 study of Acute Pain, sponsored by University of Minnesota.
NCT03587636 is a Phase 2 study of Acute Pain that has completed, run by University of Minnesota. The registered enrollment target is 77 participants, below the 266-participant average among 50 other Acute Pain trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03587636, a Phase 2 study of Acute Pain, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized prospective outcomes study comparing two groups of patients. One group will receive liposomal bupivacaine plus bupivacaine and the other will receive bupivacaine alone in interscalene blocks when undergoing total shoulder arthroplasty. The purpose of the study is to determine if LB plus bupivacaine provides superior pain control compared to bupivacaine alone when injected in an interscalene block for patients undergoing total shoulder arthroplasty surgery.
Primary Outcome
total amount of opioid use from after surgery through 72 hours. Opioids normalized to morphine equivalents
Conditions Studied
Interventions
- DRUG Bupivacaine
- DRUG liposome bupivacaine
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2021-03-17 |
| Phase | Phase 2 |
What the finished NCT03587636 record still lists
NCT03587636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 266-participant average among 50 other Acute Pain trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine is the first listed.
NCT03587636 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03587636 about?
NCT03587636 is a clinical study titled "Liposome Bupivacaine Interscalene Total Shoulder". This is a randomized prospective outcomes study comparing two groups of patients. One group will receive liposomal bupivacaine plus bupivacaine and the other will receive bupivacaine alone in interscalene blocks when undergoing total shoulder arthroplasty. The purpose of the study is to determine if...
What is the current status of trial NCT03587636?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2018-09-17. Estimated completion is 2021-03-17.
What conditions does trial NCT03587636 study?
This clinical trial studies the following conditions: Acute Pain.
What interventions are being tested in trial NCT03587636?
The interventions under investigation include: Bupivacaine (DRUG), liposome bupivacaine (DRUG).
Who is sponsoring clinical trial NCT03587636?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03587636 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03587636's enrollment target sits among peer trials
77 31st of 50 higher than 20 of 50 other Acute Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Pain From Wisdom Molar Extractions
RECRUITING · Phase 2
-
Twin Block, Pain Medications and Third Molar Extractions
RECRUITING · Phase 2
-
Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain
COMPLETED · Phase 2
-
Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED
COMPLETED · Phase 2
-
Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)
COMPLETED · Phase 2
-
A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI